Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the latest clinical results announced by Oncternal Therapeutics. Cirmtuzumab, developed by Oncternal, is an investigational antibody that blocks ROR1, or receptor tyrosine kinase-like orphan receptor 1. Normally, this receptor is not produced in healthy adult tissue, but many different cancers can reactivate its expression. This helps…
May 05, 2020May 5, 2020